Please assess the completion status of the following clinical trial:

Trial Title: NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Women ≥ 18 years old~2. Histologically or cytologically confirmed diagnosis of breast cancer~3. Naïve patients~4. Be scheduled to receive adjuvant chemotherapy with anthracycline (doxorubicin or epirubicin) + cyclophosphamide (AC-based regimen)~5. ECOG (Eastern Cooperative Oncology Group) performance status 0-2~6. Body Mass index (BMI) ≥ 18.5~7. Written informed consent~8. If women of childbearing potential age: reliable contraceptive measures must be used during the study treatment period and up to 30 days after last NEPA administration~9. Acceptable hepatic function (\<= 2 times the upper limit of normal for liver transaminases) and renal function (creatinine \< 1.5 times the upper limit of normal);~10. Ability and willingness of the patient to complete the diary.~Exclusion Criteria:~1. Advanced/metastatic breast cancer~2. Patients already submitted to non-AC-based chemotherapy~3. Treatment with investigational medications in 30 days before NEPA~4. Myocardial infarction within the last 6 months~5. Documented or known hypersensitivity to 5HT3RA (5-Hydroxytryptamine Receptor 3 Antagonists) or NK1RA (Neurokinin-1 Receptor Antagonists) and excipients~6. Uncontrolled diabetes mellitus~7. Nausea and vomiting at baseline~8. Chronic use of other antiemetic agent(s)~9. Patient's inability to take oral medication~10. Gastrointestinal obstruction or active peptic ulcer~11. Pregnancy or breastfeeding~12. Prior malignancies at other sites except surgically treated non-melanoma skin cancer, superficial cervical cancer, or other cancer from which the patient had been disease-free for ≥ 5 years~13. Psychiatric or CNS (Central Nervous System) disorders interfering with ability to comply with study protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Netupitant/Palonosetron & Dexamethasone (Type: EXPERIMENTAL): * Netupitant/Palonosetron (NEPA) will be administered orally at the dose of 300 MG (milligrams) netupitant/0.5 palonosetron 1 hour before the start of any chemotherapy cycle.~* Dexamethasone 12 mg will be added on day 1 only of each cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).